At the extraordinary general meeting in CELLINK AB (publ), held on August 6, 2021, the following resolutions were passed.

The extraordinary general meeting resolved, in accordance with the proposal by the board of directors, to change the company name from CELLINK AB (publ) to BICO AB (publ) provided registration of the Swedish Companies Registration Office and to change the company’s objects in accordance with the following; The company shall acquire, own and manage real-, movable- and intellectual property, and mainly through subsidiaries conduct development, manufacturing and sale of equipment, services, software and reagents for application in areas such as biotechnology, bioinformatics, medical technology, diagnostics and pharmacology and provide intra-group services such as coordinating financing and accounting within the Group and to conduct other business compatible therewith.

Approximately 72.9 per cent of the votes were represented at the extraordinary general meeting.

For further information, please contact:

Gusten Danielsson, CFO CELLINK
Phone (US): +1 (857) 332 2138
Phone (Sweden):
+46 709-91 86 04  

Isabelle Ljunggren, Head of Communications CELLINK
Phone: +46 708-30 08 90

The information was submitted for publication, through the agency of the contact persons set out above, at 09:10 CEST on August 6, 2021.


Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 2,000 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,700 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B.